740 related articles for article (PubMed ID: 17013997)
1. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
5. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
6. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
[TBL] [Abstract][Full Text] [Related]
7. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor-alpha-induced psoriasis.
Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
10. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
11. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
[TBL] [Abstract][Full Text] [Related]
13. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
Grinblat B; Scheinberg M
Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
[TBL] [Abstract][Full Text] [Related]
14. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
Ang HT; Helfgott S
J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
[TBL] [Abstract][Full Text] [Related]
15. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
Brown SL; Greene MH; Gershon SK; Edwards ET; Braun MM
Arthritis Rheum; 2002 Dec; 46(12):3151-8. PubMed ID: 12483718
[TBL] [Abstract][Full Text] [Related]
18. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
[TBL] [Abstract][Full Text] [Related]
20. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.
Ko JM; Gottlieb AB; Kerbleski JF
J Dermatolog Treat; 2009; 20(2):100-8. PubMed ID: 18923992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
